Compare · BTCY vs MDLN
BTCY vs MDLN
Side-by-side comparison of Biotricity Inc. (BTCY) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTCY and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $52.27B, about 365.5x BTCY ($143.0M).
- Over the past year, BTCY is up 0.0% and MDLN is down 2.3% - BTCY leads by 2.3 points.
- MDLN has been more active in the news (4 items in the past 4 weeks vs 2 for BTCY).
- MDLN has more recent analyst coverage (25 ratings vs 3 for BTCY).
PerformanceBTCY+0.00%MDLN-6.90%
2025-07-21+0.00%2025-08-01
- Company
- Biotricity Inc.
- Medline Inc.
- Price
- $0.48-25.30%
- $39.80-3.23%
- Market cap
- $143.0M
- $52.27B
- 1M return
- +0.00%
- +7.36%
- 1Y return
- +0.00%
- -2.33%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 2
- 4
- Recent ratings
- 3
- 25
BTCY
Biotricity Inc.
Biotricity, Inc., medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated electrocardiogram (ECG) device and software solution. The company is based in Redwood City, California.
Latest BTCY
- SEC Form 10-K filed by Biotricity Inc.
- SEC Form NT 10-K filed by Biotricity Inc.
- SEC Form PRE 14C filed by Biotricity Inc.
- Biotricity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Biotricity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Biotricity Inc.
- Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA
- Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th
- SEC Form S-1 filed by Biotricity Inc.
- Biotricity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Financial Officer Drazin Michael B covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)